Vanberra Signal

Kalytera Therapeutics

Curated by Signal

Developer of cannabinoid therapies for osteoporosis and bone healing

Overview

Kalytera Therapeutics is a developer of cannabinoid therapies for osteoporosis and bone healing. It focused on developing a portfolio of cannabinoid therapies with initial work on non-psychoactive cannabinoid and endocannabinoid-like medicines. It is currently working on commercializing its proprietary synthetic cannabinoid therapies across a range of disease states with an initial focus on osteoporosis and bone healing. Its lead product KAL671, synthetic fatty acid amide and an endocannabinoid-like molecule licensed from Yissum Research Development Company restore bone in persons suffering from osteoporosis are in the research phase.

Key facts

Founded
2014

Contact

More on Vanberra Signal

Members only

Competitors & similar companies

More Health Technology companies
  • Provider of a mobile application for guided meditations, Tarot cards, and daily affirmations

    Health TechnologyWilmington, United States
  • Cloud computing statistical reasoning platform based on Machine Learning / Deep Learning driven Cognitive Computing for healthcare

    Health TechnologyPotomac, United States
  • Provider of cloud-based practice management software for healthcare providers

    Health TechnologyMiami, United States

About Kalytera Therapeutics

What does Kalytera Therapeutics do?

Kalytera Therapeutics is a developer of cannabinoid therapies for osteoporosis and bone healing.

Where is Kalytera Therapeutics headquartered?

Kalytera Therapeutics is headquartered in San Rafael, United States.

When was Kalytera Therapeutics founded?

Kalytera Therapeutics was founded in 2014.

Which sector is Kalytera Therapeutics in?

Kalytera Therapeutics operates in Health Technology.

Who are Kalytera Therapeutics's competitors?

Companies similar to Kalytera Therapeutics include AB.Money, Ingine, and Cima Connected Life.